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Exclusive abdominal lymphadenopathy as a rare presentation of sarcoidosis
Linfadenopatia abdominal exclusiva como apresentação rara de sarcoidose
Matheus de Carvalho Santos1, Ana Júlia Araujo de Carvalho1, Helena Telles Furtado dos 
Santos1, Matheus Heringer Gomes1, Thiago Arruda Rezende2
Santos MC, Carvalho AJA, Santos HTF, Gomes MH, Rezende TA. Exclusive abdominal lymphadenopathy as a rare presentation 
of sarcoidosis / Linfadenopatia abdominal exclusiva como apresentação rara de sarcoidose. Rev Med (São Paulo). 2018 Nov-
Dec;97(6):585-8.
Case Report. Oswaldo Cruz Awards. XXXVII Congresso Médico Universitário, Faculdade de Medicina da USP, SP, Sept. 2018.
1. Student author. Univsersidade Federal de Uberlândia / Federal University of Uberlandia. ORCID: Santos MC - https://orcid.org/0000-0003-0033-
0387; Carvalho AJA - https://orcid.org/0000-0003-3735-1843; Santos HTF - https://orcid.org/0000-0001-5892-911X; Gomes MH - https://orcid.
org/0000-0002-9488-7225.
2. Academic advisor. Universidade Federal de Uberlândia (UFU) / Federal University of Uberlandia.
Corresponding author: Matheus de Carvalho Santos. Rua Franscisco Antônio de Oliveira, 1211. Uberlândia, MG, Brazil. E-mail: matheuscs@ufu.br.
ABSTRACT: Introduction: Sarcoidosis is a systemic granulomatous 
disease. The disease’s immunopathogenic mechanism is the activation 
of a cell mediated immune response. Lung is the most affected organ, 
but up to 30% of patients can have extrapulmonary manifestations. Case 
report: A 21-year-old male presented with a history of nausea, vomiting 
after meals, epigastric and periumbilical pain for approximately 6 
months. Hyporexia and loss of 35 kilograms in 7 months were present, 
in addition to intermittent low nocturnal fever. His computed tomography 
(CT) scan (Figure 1) of the abdomen showed the presence of multiple, 
enlarged mesenteric lymph nodes with homogenous shape, measuring 
up to 2.0 cm in diameter, extending from the upper abdomen to the 
pelvis. Histopathologic findings of this lymph nodes showed a sarcoid 
appearance (Figure 2). Lymphoma, tuberculosis and other infections 
were excluded through immunohistochemical analysis. Treatment with 
prednisone was started initially at a dose of 40mg and after 5 weeks the 
patient were asymptomatic. One year and three months after the onset 
of treatment, corticosteroid dose reduction was attempted 3 times, with 
all of them leading to disease relapses. Treatment was optimized with 
60mg of prednisone (for 2 weeks) plus 100mg of azathioprine daily. 
Discussion: The prevalence of gastrointestinal system involvement 
with clinical manifestations is 0,1 to 0,9%. However, the incidence of 
subclinical involvement can be higher. Enlarged lymph nodes is present 
in approximately 30% of cases. Treatment is indicated in sarcoidosis for 
patients with damage organ function or symptomatic disease and the 
first-line therapy is corticosteroid.
Keywords: Sarcoidosis/therapy; Lymphadenopathy/therapy. 
RESUMO: Introdução: A sarcoidose é uma doença granulomatosa 
sistêmica, sendo que o seu mecanismo imunopatogênico se dá através 
da ativação de uma resposta imune mediada por células. O pulmão é o 
órgão mais afetado, porém até 30% dos pacientes podem ter manifestações 
extrapulmonares. Relato de Caso: Um homem jovem de 21 anos iniciou 
com um quadro de náuseas, vômitos pós-alimentares e dor epigástrica e 
periumbilical por aproximadamente 6 meses. Havia também a presença 
de hiporexia e perda ponderal de 35 kg em 7 meses, além de febre baixa 
diária no período da noite. A tomografia computadorizada (TC) da região 
abdominal mostrou a presença de múltiplos linfonodos mesentéricos 
aumentados de tamanho, com formato homogêneo, medindo até 2,0 cm 
de diâmetro, se estendendo do abdome superior até a pelve. A análise 
histopatológica desses linfonodos evidenciou uma aparência sarcoide, 
sendo que linfoma, tuberculose e outras doenças infecciosas foram 
excluídas através de análise imuno-histoquímica. O tratamento foi iniciado 
com prednisona inicialmente na dose de 40 mg diariamente e depois de 
5 semanas o paciente estava assintomático. Um ano e três meses depois 
do início do tratamento a redução da dose do corticoide foi tentada por 
3 vezes, com todas elas levando à recidivas da doença. O tratamento foi, 
então, otimizado com 60 mg de prednisona (por 2 semanas) com 100 mg 
de azatioprina diariamente. Discussão: A prevalência do envolvimento 
do sistema gastrointestinal na sarcoidose com manifestações clínicas é de 
0,1 a 0,9%. Entretanto, a incidência de envolvimento subclínico pode ser 
maior do que isso. A linfonodomegalia está presente em aproximadamente 
30% dos casos. O tratamento da sarcoidose está indicado para aqueles 
pacientes com lesão funcional de órgãos ou doença sintomática, sendo 
os corticoides a primeira linha de terapia indicada. 
Descritores: Sarcoidose/terapia; Linfadenopatia/terapia. 
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INTRODUCTION
Sarcoidosis is a systemic granulomatous disease characterized by the presence of noncaseating 
granulomas in many organs, mainly the lungs. The 
prevalence of disease varies according to race, age and 
geographic regions, being more prevalent among young and 
middle age adults (e.g. 70% of patients aged 25-45 years), 
northern European and African–American individuals1,2,3.
The etiology and pathogenesis are still not 
defined, but studies suggested that environmental and 
genetic susceptibility contribute to disease development. 
Mycobacteria and propionibacteria have been identified as 
possible causative agents. Other environmental factors are 
related to exposure to emissions from wood-burning stoves, 
tree pollen, insecticides and moldy environments. Some 
genes are referred to be associated with sarcoidosis, such 
as HLA-B8, HLA-DRB1 and DQB1 alleles, butyrophilin-
like 2 (BTNL2) 1,2,3.
The immunopathogenic mechanism is related 
to the activation of a cell mediated immune response, 
leading to granuloma formation and distortion of normal 
microarchitecture. In sarcoidosis, there is activation of type 
1 T helper cells that secrete predominantly interleukin-2 and 
interferon-γ, increase in macrophage TNF-α production, 
and amplification of the local cellular immune response. 
Also, studies found a reduced number of regulatory T cells 
and natural killer T cells in the peripheral blood of patients 
with sarcoidosis1,2,3.
Lung is the most affected organ, with statistics 
indicating that 90% of patients with sarcoidosis have 
some kind of thoracic involvement. Symmetrical hilar 
adenopathy is the most common thoracic manifestation 
and diffuse interstitial lung disease is the classic type 
of lung involvement, but patients can present with 
pneumothorax, pleural thickening, chylothorax and 
pulmonary hypertension4. Up to 30% of patients can have 
extrapulmonary manifestations and the most common sites 
are skin, eyes, reticuloendothelial system, musculoskeletal 
system, exocrine glands, heart, kidney and central nervous 
system. Systemic symptoms such as fatigue, night sweats, 
and weight loss are common5.
Diagnostic of sarcoidosis is made based on three 
criteria: compatible clinical and radiological presentation, 
histopathologic detection of noncaseating granulomas and 
exclusion of other diseases that may present similarly. The 
decision to treat sarcoidosis is based on the activity and 
extent of disease, being the use of immunosuppressive 
agents, mainly corticosteroids, the treatment of choice6.
CASE REPORT
A 21-year-old male showed up with a history of 
nausea and vomiting after meals, up to four times a day for 
approximately 6 months. He also had moderate to severe 
epigastric and periumbilical pain, which improved after 
eating and worsened with fasting. Hyporexia and loss of 35 
kilograms in 7 months were present, in addition to weekly 
intermittent low nocturnal fever.
Initially, increased CRP (C-Reactive Protein) and 
ESR (erythrocyte sedimentation rate) were detected (40mg/
dl CRP and 87mm ESR), plus an iron deficiency anemia. 
The patient underwent proton pump inhibitor use for 6 
weeks without any improvement. Endoscopic examination 
revealed pangastritis and moderate duodenitis.
After these findings, a computed tomography 
(CT) scan (Figure 1) of the abdomen was requested and 
showed the presence of multiple, enlarged mesenteric 
lymph nodes with homogenous shape, measuring up to 
2.0 cm in diameter, extending from the upper abdomen, 
peripancreatic, paraaortic to the pelvis. Chest CT showed 
no lymphadenomegaly. It was also requested an entero-
tomography which showed normal intestinal loops, but 
confirmed the previously detected lymphadenomegaly. In 
view of these results, excisional biopsy of a few lymph 
nodes was performed through video laparoscopy. At 
the microscope, the lymph nodes resembled a sarcoid 
appearance (Figure 2), indicating sarcoidosis which was 
exclusive to the retroperitoneal lymph nodes. In addition, 
lymphoma, tuberculosis and other infections were excluded 
through immunohistochemical analysis.
Figure 1: Computed tomography (CT) scan showing multiple 
enlarged abdominal lymph nodes (white arrows) 
Figure 2: Microscopic view of an excised lymph node showing 
the characteristic sarcoid appearance
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Treatment with an oral systemic corticosteroid 
(prednisone) was started initially at a dose of 40mg. After 
2 weeks, the patient reported symptomatic improvement 
and after 5 weeks the patient reported to be asymptomatic. 
Magnetic resonance imaging and control laboratory tests 
became normal.
One year and three months after the onset of 
treatment, corticosteroid dose reduction was attempted 
3 times, with all of them leading to disease relapses 
consisting of recurrence of symptoms. Routine laboratory 
exams exhibited signs of inflammation (though milder than 
before treatment) and a new CT was performed showing 
abdominal lymphadenomegaly with the same previous 
characteristics.
Treatment was optimized with 60mg of prednisone 
(for 2 weeks) plus 100mg of azathioprine daily. After 
this initial period, the patient reported symptomatic 
improvement, with the latest information given is that the 
patient is almost asymptomatic as of now.
DISCUSSION
Sarcoidosis is a systemic disease of unknown 
etiology, characterized by the formation of noncaseating 
granulomas. Although pulmonary involvement is the most 
common, 30% of patients present with extrapulmonary 
sarcoidosis, being the abdomen the most common 
extrathoracic site (50-70%)7.
The prevalence of gastrointestinal system 
involvement in sarcoidosis with clinical manifestations 
is 0,1 to 0,9%6. However, the incidence of subclinical 
involvement can be higher, since gastrointestinal 
involvement is normally underdiagnosed because patients 
with sarcoidosis generally do no present with abdominal 
symptomatology8.
The symptoms of gastrointestinal sarcoidosis 
may occur in patients who are already diagnosed with 
the disease in other organs or they can represent the 
initial manifestation. The most common symptoms 
of gastrointestinal sarcoidosis are nausea, vomiting, 
weight loss, diarrhea, and epigastric pain. In addition, 
gastrointestinal forms can include: periumbilical pain, 
fever, dysphagia, hoarseness and odynophagia6.
Enlarged lymph nodes are present in approximately 
30% of cases, being paraaortic, portal, peripancreatic and 
epigastric the most affected8. The lymph nodes are typically 
smaller than 2 cm in diameter and more discrete rather than 
confluent, the involvement of the retrocrural area is less 
common. The characteristics of this lymph nodes on CT are: 
soft tissue attenuation, mildly enhanced with gadolinium in 
T1 images and homogeneously hyperintense appearance or 
central hypointensity surrounded by peripheral high signal 
intensity on T2 images7.
These features of gastrointestinal sarcoidosis make 
the disease a differential diagnosis with neoplastic or 
infectious disease, such as lymphoma, granulomatous or 
mycobacterial infections, fungal and parasitic infections, 
Whipple’s disease and Crohn’s disease7.
Abdominal sarcoidosis can occur in the absence 
of pulmonary disease, as shown in this case7. This patient 
presented with epigastric and periumbilical pain, nausea, 
vomiting and weight loss. His CT showed enlargement of 
mesenteric, paraaortic, peripancreatic and pelvic lymph 
nodes and the histopathologic findings were consistent with 
sarcoidosis. Also, other diseases that can present similarly 
were excluded from the diagnosis. Therefore, all the three 
criteria to meet the diagnosis of sarcoidosis were filled: the 
patient had a compatible clinical presentation, radiological 
features consistent with gastrointestinal sarcoidosis and the 
findings of noncaseating granulomas upon histopathologic 
exam.
Treatment is indicated in sarcoidosis for patients 
whose organ function is threatened or in symptomatic 
disease, as the patient in this case presented9. Treatment 
is not indicated in all cases because the disease can be 
self-limiting and have a spontaneous remission within 2–3 
years in a majority of patients10. The decisions about the 
treatment of sarcoidosis still are a challenge: there is still 
not a protocol validated to institute, maintain and tapper 
down the therapy, besides the vast majority of studies is 
destined only or mainly towards pulmonary sarcoidosis. 
First-line therapy consists in the use of glucocorticoids and 
glucocorticosteroid-like agents9.
An international consensus statement recommends 
initiating treatment with oral prednisone at a dose of 20 
to 40 mg per day for four to six weeks. If the patient 
presents a response to treatment, dosage should be 
tapered slowly to approximately 5 to 10 mg per day and 
this should be continued for 12 months9. Recent studies 
show that alternative corticosteroid therapy may be 
necessary, especially if the patient is refractory or if there 
is a need to spare the use of corticosteroid because of its 
side effects, such as excessive weight gain, osteoporosis, 
diabetes mellitus, hypertension, gastritis, myopathy and 
opportunistic infections10,11,13.
As the patient in this case presented with relapses 
after trying to taper prednisone, second-line agents 
were included in his therapy: cytotoxic agents, such as 
methotrexate, azathioprine, leflunomide and antimalarials 
drugs.13 Methotrexate is considered to be the first-choice 
option in sarcoidosis, because there is a large number 
of trials supporting its use for both pulmonary and 
extrapulmonary disease, although, a retrospective trial 
compared the effects of azathioprine and methotrexate in 
pulmonary sarcoidosis and it concluded that medications 
had similar effects and both presented substantial steroid-
sparing capacities and comparable side-effect profiles, 
except for a higher rate of infections with azathioprine10,11,12.
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Studies about pulmonary sarcoidosis show that the 
disease resolves spontaneously within 2 years and after 
5 years the remission is much less likely. Relapses after 
treatment are common and most often occur two to six 
months after corticosteroid withdrawal, but rarely after 
three years without symptoms9.
This case was searched in the main databases of the 
global medical literature and practically no original material 
was found. The incidence of sarcoidosis in the described 
form (intra-abdominal lymph node involvement not 
associated with GI mucosal disease and without pulmonary 
involvement) is extremely uncommon, a factor that 
caused the diagnosis process to take about 6 months to be 
obtained. In addition, the case shows the importance of the 
differential diagnosis of abdominal lymphadenopathy, since 
this finding can translate into the most diverse pathologies 
that can have completely different therapeutic management.
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